Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141118 | 1.00 | SIGMAR1 (0.48) | SIGMAR1ACHESCN4ACYP1A2CYP3A4 | |
| SCHEMBL7518873 | 0.85 | DRD2 (0.57) | SIGMAR1SCN4A | |
| SCHEMBL12975924 | 0.79 | FUCA1 (0.53) | SIGMAR1ACHESCN4ABCHEBACE1 | |
| SCHEMBL13999717 | 0.78 | DRD2 (0.50) | SIGMAR1ACHEPOLB | |
| SCHEMBL13406114 | 0.78 | ACHE (0.58) | SIGMAR1ACHECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3631358 | 0.78 | DRD2 (0.50) | SIGMAR1ACHEPOLB | |
| SCHEMBL13406112 | 0.78 | ACHE (0.58) | SIGMAR1ACHECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2883130 | 0.78 | SIGMAR1 (0.54) | SIGMAR1ACHESCN4APOLBOPRL1 | |
| SCHEMBL6334669 | 0.77 | SIGMAR1 (0.43) | SIGMAR1ACHESCN4ABCHEBACE1 | |
| SCHEMBL6339678 | 0.77 | SIGMAR1 (0.43) | SIGMAR1ACHESCN4ABCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | SIGMAR1 5/4885ACHE 882/4885SCN4A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.